



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

21st October 2020

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Re: Compliance of Clause 40(9) of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR),

As required under Clause 40(9) of the Listing Obligations and Disclosure Requirements Regulations, 2015 (**LODR**), we are enclosing herewith copy of the certificate issued by Manish Ghia & Associates, Practicing Company Secretaries, for the period 1st April 2020 to 30th September 2020, certifying that all certificates have been issued within thirty days of the date of lodgment for transfer, sub-division, consolidation, renewal, exchange or endorsement of calls/allotment monies.

Thanking you,

Yours faithfully
For GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

Encl:

**CERTIFICATE UNDER REGULATION 40 (9) OF SECURITIES AND EXCHANGE BOARD OF INDIA
(LISTING OBLIGATIONS AND DISCLOSURES REQUIREMENTS) REGULATIONS, 2015
FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2020**

TO WHOMSOEVER IT MAY CONCERN

We have examined all Share Transfer Forms, Memorandum of Transfers, Registers, files and other documents relating to **Glaxosmithkline Pharmaceuticals Limited** having its registered office at GSK House, Dr Annie Besant Road, Worli, Mumbai - 400030 maintained by **KFin Technologies Private Limited (formerly known as Karvy Fintech Private Limited)**, the Registrar & Share Transfer Agent (RTA) of the Company pertaining to transfer of equity shares of the Company for the period from **1st April, 2020 to 30th September, 2020** for the purpose of issuing Certificate as per Regulation 40 (9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 by **Glaxosmithkline Pharmaceuticals Limited** and based on information provided by the Company, we hereby certify that during the half year ended on **30th September, 2020** the Company:

- a) has issued Share Certificate(s) relating to request(s) for sub-division /split of share certificate(s) received during the said half year (from 1st April, 2020 to 30th September, 2020) within thirty days from the respective date(s) of receipt of such request(s) except those rejected on technical grounds;
- b) has issued Share Certificate(s) relating to request(s) for Issue of Duplicate Share Certificate(s) in lieu of original lost/misplaced, Consolidation of Share Certificate and Renewal of Share Certificate received during the said half year (from 1st April, 2020 to 30th September, 2020) within thirty days from the respective date(s) of receipt of such request(s) except those rejected on technical grounds; and
- c) has not received any request for transfer, consolidation, renewal, exchange or endorsement of calls/allotment monies.

Place: Mumbai
Date: October 21, 2020
UDIN: F006252B001015887



**For Manish Ghia & Associates
Company Secretaries**

MANISH
LALITCHAN
DRA GHIA

Digitally signed by
MANISH
LALITCHANDRA GHIA
Date: 2020.10.21
11:17:24 +05'30'

**CS Manish L. Ghia
Partner**

M. No. FCS 6252 C.P. No. 3531

Note: Due to lockdown (on account of COVID - 19 Pandemic), we have not been able to carry out physical visit to RTA office for verification of data. The Certificate is based on inputs received via email from RTA and oral confirmation with RTA.